10-K: Semler Scientific Reports Strong 2024 Results, Bolsters Bitcoin Treasury Strategy

Semler Scientific's 2024 annual report reveals increased net income driven by its healthcare technology solutions and strategic bitcoin investments.

Summary

• Semler Scientific, Inc. reported total revenues of $56.3 million and net income of $40.9 million for the year ended December 31, 2024, compared to $68.2 million and $20.6 million in 2023.
• The company adopted bitcoin as its primary treasury reserve asset in May 2024, holding approximately 2,298 bitcoins as of December 31, 2024, acquired at an aggregate purchase price of $189.7 million.
• As of February 14, 2025, Semler held approximately 3,192 bitcoins acquired at an aggregate purchase price of $280.4 million.
• The company is seeking a new 510(k) clearance from the FDA for expanded use of QuantaFlo to aid in the diagnosis of other cardiovascular diseases.
• In January 2025, Semler issued $100 million in convertible senior notes due 2030 to further its bitcoin acquisition strategy.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While net income increased, revenues decreased, and the company faces regulatory and market risks associated with its bitcoin strategy and healthcare operations. The capital raise is a positive but also adds debt.

Positives

• Net income increased significantly year-over-year.
• The company has adopted a bitcoin treasury strategy, viewing bitcoin as a reliable store of value.
• Semler is actively seeking FDA clearance for expanded use of its QuantaFlo product.
• The company has successfully raised capital through equity and debt offerings.
• The company maintains a positive relationship with its employees.

Negatives

• Revenues decreased from $68.2 million in 2023 to $56.3 million in 2024.
• The company is experiencing decreased usage of QuantaFlo due to changes in the CMS reimbursement landscape.
• The bitcoin treasury strategy exposes the company to the volatility of bitcoin prices.
• The company is at risk of civil suit by the DOJ related to claims for reimbursement related to its QuantaFlo device.
• The company relies on a small number of independent suppliers and facilities for the manufacturing of QuantaFlo.

Risks

• The company's bitcoin treasury strategy exposes it to risks associated with bitcoin's volatility and regulatory uncertainty.
• The company is subject to healthcare fraud and abuse laws and regulations, and is at risk of a civil False Claims Act lawsuit.
• The company relies heavily on a small number of key personnel.
• The company's future financial performance depends on successful improvements and software updates to QuantaFlo.
• The company operates in a competitive and rapidly changing business environment.

Future Outlook

The company expects to continue to experience decreased usage of QuantaFlo due to changes in the CMS reimbursement landscape, which is expected to have a negative effect on revenues. Semler intends to continue to accumulate bitcoin and monitor market conditions.

Industry Context

The announcement reflects a growing trend of companies diversifying treasury reserves into alternative assets like bitcoin. The company's focus on healthcare technology solutions aligns with the increasing demand for cost-effective wellness programs and chronic disease management.

Comparison to Industry Standards

• Semler's adoption of Bitcoin as a primary treasury reserve asset is a unique strategy, not commonly seen among its medical device peers.
• Comparable companies in the medical device industry, such as Medtronic or Abbott, typically invest in traditional assets like government bonds and high-grade corporate debt.
• The company's revenue decline contrasts with the growth seen in some segments of the medical device industry, potentially due to reimbursement challenges.
• The company's bitcoin strategy is more akin to that of MicroStrategy, a software company that has heavily invested in bitcoin as a treasury reserve asset.

Legal Proceedings

• The company is cooperating with a DOJ investigation related to claims for reimbursement related to its QuantaFlo device and is at risk of a civil suit by the DOJ.

Related Party Transactions

• On May 17, 2023, the company acquired outstanding warrants to acquire 76,875 shares of its common stock from its chief executive officer for $1.9 million in cash.

Stakeholder Impact

• Shareholders face potential dilution from the conversion of the senior convertible notes.
• Employees may be affected by the company's strategic streamlining efforts.
• Customers may experience changes in the availability or pricing of QuantaFlo due to reimbursement landscape changes.
• Suppliers may be impacted by the company's reliance on a small number of independent contractors.

Next Steps

• The company will continue to monitor market conditions in determining whether to engage in additional bitcoin purchases.
• The company intends to vigorously defend itself in any legal action related to the DOJ investigation.
• The company will continue to explore potential new product and service offerings through its research and development programs.

Key Dates